Clinical Value and Potential Mechanism of miRNA-33a-5p in Lung Squamous Cell Carcinoma

Figure 2

miRNA-33a-5p overexpression in LUSC and its association with clinicopathological parameters based on TCGA. (a) The expression of miRNA-33a-5p in LUSC and nontumor tissues based on TCGA. (b) The ROC curve was generated to assess the diagnostic ability of miRNA-33a-5p in LUSC and noncancerous lung tissues. (c) The expression of miRNA-33a-5p in LUSC and nontumor tissues for female patients based on TCGA. (d) The ROC curve of miRNA-33a-5p expression in female patients based on TCGA. (e) The expression of miRNA-33a-5p in LUSC and nontumor tissues for male patients based on TCGA. (f) The ROC curve of miRNA-33a-5p expression in male patients based on TCGA. (g) The expression of miRNA-33a-5p for age of LUSC patients. (h) The ROC curve of miRNA-33a-5p for age of LUSC. (i) The expression of miRNA-33a-5p in LUSC and nontumor tissues for different age of female patients based on TCGA. (j) The ROC curve of miRNA-33a-5p expression in different age of female patients based on TCGA. (k) The expression of miRNA-33a-5p in early (T1–T2) and late (T3–T4) T stages of LUSC. (l) The ROC curve of miRNA-33a-5p for T stages of LUSC. AUC: area under the curve; CI: confidence interval; LUSC: lung squamous cell carcinoma; ROC: receiver operating characteristic; TCGA: The Cancer Genome Atlas.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)